Alterations in Gene Expression of Proprotein Convertases in Human Lung Cancer Have a Limited Number of Scenarios

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Demidyuk, Ilya V ^a   Shubin, Andrey V ^a   Gasanov, Eugene V ^a   Kurinov, Alexander M ^a   Demkin, Vladimir V ^a   Vinogradova, Tatyana V ^b   Zinovyeva, Marina V ^b   Sass, Alexander V ^b   Zborovskaya, Irina B ^c   Kostrov, Sergey V ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

^b SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

FURIN; GELATINASE A; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; SERINE PROTEINASE; TUMOR MARKER;

ARTICLE; CANCER INVASION; CANCER TISSUE; CLINICAL ARTICLE; CLUSTER ANALYSIS; ENZYME SUBSTRATE; FURIN GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; MMP14 GENE; MMP2 GENE; PCSK1 GENE; PCSK2 GENE; PCSK3 GENE; PCSK4 GENE; PCSK5 GENE; PCSK6 GENE; PCSK7 GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SAMPLE;

CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PROPROTEIN CONVERTASES;

EID: 84873593525     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055752     Document Type: Article

References (66)

1. Seidah NG, (2011) What lies ahead for the proprotein convertases? Ann N Y Acad Sci 1220: 149-161.
2. Creemers JW, Khatib AM, (2008) Knock-out mouse models of proprotein convertases: unique functions or redundancy? Front Biosci 13: 4960-4971.
3. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ, (2005) Proprotein convertases: "master switches" in the regulation of tumor growth and progression. Mol Carcinog 44: 151-161.
4. Chretien M, Seidah NG, Basak A, Mbikay M, (2008) Proprotein convertases as therapeutic targets. Expert Opin Ther Targets 12: 1289-1300.
5. Schalken JA, Roebroek AJ, Oomen PP, Wagenaar SS, Debruyne FM, et al. (1987) fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest 80: 1545-1549.
6. Creemers JW, Roebroek AJ, Van de Ven WJ, (1992) Expression in human lung tumor cells of the proprotein processing enzyme PC1/PC3. Cloning and primary sequence of a 5 kb cDNA. FEBS Lett 300: 82-88.
7. Scopsi L, Gullo M, Rilke F, Martin S, Steiner DF, (1995) Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. J Clin Endocrinol Metab 80: 294-301.
8. Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M, (1997) Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 75: 1509-1514.
9. Hubbard FC, Goodrow TL, Liu SC, Brilliant MH, Basset P, et al. (1997) Expression of PACE4 in chemically induced carcinomas is associated with spindle cell tumor conversion and increased invasive ability. Cancer Res 57: 5226-5231.
10. Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, et al. (1997) Pro-protein convertase gene expression in human breast cancer. Int J Cancer 71: 966-971.
11. Rounseville MP, Davis TP, (2000) Prohormone convertase and autocrine growth factor mRNAs are coexpressed in small cell lung carcinoma. J Mol Endocrinol 25: 121-128.
12. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, et al. (2001) Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 31: 224-232.
13. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98: 13790-13795.
14. Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao J, et al. (2002) Gene expression in epithelial ovarian carcinoma. Oncogene 21: 6289-6298.
15. Fu Y, Campbell EJ, Shepherd TG, Nachtigal MW, (2003) Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 1: 569-576.
16. Lopez de Cicco R, Watson JC, Bassi DE, Litwin S, Klein-Szanto AJ, (2004) Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression. Clin Cancer Res 10: 4480-4488.
17. Tzimas GN, Chevet E, Jenna S, Nguyen DT, Khatib AM, et al. (2005) Abnormal expression and processing of the proprotein convertases PC1 and PC2 in human colorectal liver metastases. BMC Cancer 5: 149.
18. Page RE, Klein-Szanto AJ, Litwin S, Nicolas E, Al-Jumaily R, et al. (2007) Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 29: 289-299.
19. Shibru D, Hwang J, Khanafshar E, Duh QY, Clark OH, et al. (2008) Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? Cancer 113: 930-935.
20. Estilo CL, O-charoenrat P, Talbot S, Socci ND, Carlson DL, et al. (2009) Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9: 11.
21. D'Anjou F, Routhier S, Perreault JP, Latil A, Bonnel D, et al. (2011) Molecular validation of PACE4 as a target in prostate cancer. Transl Oncol 4: 157-172.
22. (2009) WHO Fact Sheet N 297.
23. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, et al. (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824.
24. Raponi M, Zhang Y, Yu J, Chen G, Lee G, et al. (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66: 7466-7472.
25. Kuner R, Muley T, Meister M, Ruschhaupt M, Buness A, et al. (2009) Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer 63: 32-38.
26. Valk K, Vooder T, Kolde R, Reintam MA, Petzold C, et al. (2010) Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers. Oncology 79: 283-292.
27. Sato H, Takino T, (2010) Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci 101: 843-847.
28. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M, (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 393: 101-104.
29. Remacle AG, Rozanov DV, Fugere M, Day R, Strongin AY, (2006) Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP. Oncogene 25: 5648-5655.
30. Koo BH, Kim HH, Park MY, Jeon OH, Kim DS, (2009) Membrane type-1 matrix metalloprotease-independent activation of pro-matrix metalloprotease-2 by proprotein convertases. FEBS J 276: 6271-6284.
31. Chomczynski P, Mackey K, (1995) Modification of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. Biotechniques 19: 942-945.
32. Zhu YY, Machleder EM, Chenchik A, Li R, Siebert PD, (2001) Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction. Biotechniques 30: 892-897.
33. Pavlidis P, Noble WS, (2003) Matrix2png: a utility for visualizing matrix data. Bioinformatics 19: 295-296.
34. Seidah NG, Day R, Hamelin J, Gaspar A, Collard MW, et al. (1992) Testicular expression of PC4 in the rat: molecular diversity of a novel germ cell-specific Kex2/subtilisin-like proprotein convertase. Mol Endocrinol 6: 1559-1570.
35. Torii S, Yamagishi T, Murakami K, Nakayama K, (1993) Localization of Kex2-like processing endoproteases, furin and PC4, within mouse testis by in situ hybridization. FEBS Lett 316: 12-16.
36. Tadros H, Chretien M, Mbikay M, (2001) The testicular germ-cell protease PC4 is also expressed in macrophage-like cells of the ovary. J Reprod Immunol 49: 133-152.
37. Seidah NG, Gaspar L, Mion P, Marcinkiewicz M, Mbikay M, et al. (1990) cDNA sequence of two distinct pituitary proteins homologous to Kex2 and furin gene products: tissue-specific mRNAs encoding candidates for pro-hormone processing proteinases. DNA Cell Biol 9: 415-424.
38. Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, et al. (2002) Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer 35: 249-255.
39. Atkinson JM, Pennington CJ, Martin SW, Anikin VA, Mearns AJ, et al. (2007) Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer 43: 1764-1771.
40. Gruber MP, Coldren CD, Woolum MD, Cosgrove GP, Zeng C, et al. (2006) Human lung project: evaluating variance of gene expression in the human lung. Am J Respir Cell Mol Biol 35: 65-71.
41. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, et al. (2005) Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167: 1763-1775.
42. Kessenbrock K, Plaks V, Werb Z, (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
43. Gialeli C, Theocharis AD, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27.
44. Nakagawa H, Yagihashi S, (1994) Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung. Jpn J Cancer Res 85: 934-938.
45. Polette M, Nawrocki B, Gilles C, Sato H, Seiki M, et al. (1996) MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 428: 29-35.
46. Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, et al. (1997) Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 72: 556-564.
47. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS, (2000) Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190: 150-156.
48. Cox G, Jones JL, Andi A, Waller DA, O'Byrne KJ, (2001) A biological staging model for operable non-small cell lung cancer. Thorax 56: 561-566.
49. Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, et al. (2004) Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 10: 6579-6585.
50. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, et al. (2006) Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2-complex or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 236: 125-132.
51. Leinonen T, Pirinen R, Bohm J, Johansson R, Kosma VM, (2008) Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol 23: 693-700.
52. Eren B, Sar M, Oz B, Dincbas FH, (2008) MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas. Ann Acad Med Singapore 37: 32-39.
53. Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, et al. (2008) The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 40: 1111-1125.
54. Linnoila RI, Mulshine JL, Steinberg SM, Funa K, Matthews MJ, et al. (1988) Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol 90: 641-652.
55. Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, et al. (1989) Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 7: 1614-1620.
56. Skov BG, Sorensen JB, Hirsch FR, Larsson LI, Hansen HH, (1991) Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 2: 355-360.
57. Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, et al. (1993) Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 10: 209-219.
58. Linnoila RI, Piantadosi S, Ruckdeschel JC, (1994) Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 106: 367S-371S.
59. Pujol JL, Boher JM, Grenier J, Quantin X, (2001) Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31: 221-231.
60. Hiroshima K, Iyoda A, Shibuya K, Toyozaki T, Haga Y, et al. (2002) Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg 73: 1732-1735.
61. Pelosi G, Pasini F, Sonzogni A, Maffini F, Maisonneuve P, et al. (2003) Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer 97: 2487-2497.
62. Howe MC, Chapman A, Kerr K, Dougal M, Anderson H, et al. (2005) Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 46: 195-201.
63. Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, et al. (2007) Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance. Am J Surg Pathol 31: 26-32.
64. Segawa Y, Takata S, Fujii M, Oze I, Fujiwara Y, et al. (2009) Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol 135: 1055-1059.
65. Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G, et al. (2009) Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 455: 125-132.
66. Yuasa K, Suzue K, Nagahama M, Matsuda Y, Tsuji A, (2007) Transcriptional regulation of subtilisin-like proprotein convertase PACE4 by E2F: possible role of E2F-mediated upregulation of PACE4 in tumor progression. Gene 402: 103-110.